About iTeos Therapeutics
iTeos Therapeutics is a company based in Cambridge (United States) founded in 2011 was acquired by Concentra Biosciences in July 2025.. iTeos Therapeutics has raised $204.31 million across 9 funding rounds from investors including Pfizer, Janus Henderson Investors and RTW Investments. The company has 32 employees as of December 31, 2022. iTeos Therapeutics offers products and services including Belrestotug (EOS-448), EOS-984, and EOS-215. iTeos Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Cambridge, United States
- Employees 32 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Iteos Therapeutics Inc
-
Annual Revenue
$35 M178as on Dec 31, 2024
-
Net Profit
$-134.41 M-19as on Dec 31, 2024
-
EBITDA
$-159.53 M-6as on Dec 31, 2024
-
Total Equity Funding
$204.31 M (USD)
in 9 rounds
-
Latest Funding Round
$125.36 M (USD), Series B
Apr 01, 2020
-
Investors
Pfizer
& 19 more
-
Employee Count
32
as on Dec 31, 2022
-
Acquired by
Concentra Biosciences
(Jul 21, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of iTeos Therapeutics
iTeos Therapeutics offers a comprehensive portfolio of products and services, including Belrestotug (EOS-448), EOS-984, and EOS-215. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Immunotherapy targeting immune checkpoints for cancer treatment.
Drug candidate enhancing anti-tumor immune responses in trials.
Under development for advanced malignancies in clinical studies.
Unlock access to complete
Leadership Team
14 people
Scientific Team
4 people
Software Development Team
4 people
Operations Team
3 people
Product Management Team
3 people
Human Resources and Administration
2 people
Finance and Accounting
2 people
CMC Team
1 people
Unlock access to complete
Funding Insights of iTeos Therapeutics
iTeos Therapeutics has successfully raised a total of $204.31M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $125.36 million completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Series B — $125.4M
-
First Round
First Round
(01 Dec 2011)
- Investors Count 19
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2020 | Amount | Series B - iTeos Therapeutics | Valuation | RA Capital Management , Boxer Capital | |
| Jan, 2020 | Amount | Grant - iTeos Therapeutics | Valuation |
investors |
|
| Jun, 2018 | Amount | Series B - iTeos Therapeutics | Valuation | MPM Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in iTeos Therapeutics
iTeos Therapeutics has secured backing from 20 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, Janus Henderson Investors and RTW Investments. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech startups are funded by this venture capital firm.
|
Founded Year | Domain | Location | |
|
Life Sciences focused VC firm investing in the US
|
Founded Year | Domain | Location | |
|
Multiple sectors are targeted for venture capital investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by iTeos Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - iTeos Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Iteos Therapeutics Comparisons
Competitors of iTeos Therapeutics
iTeos Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Iteos Therapeutics
Frequently Asked Questions about iTeos Therapeutics
When was iTeos Therapeutics founded?
iTeos Therapeutics was founded in 2011.
Where is iTeos Therapeutics located?
iTeos Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is iTeos Therapeutics a funded company?
iTeos Therapeutics is a funded company, having raised a total of $204.31M across 9 funding rounds to date. The company's 1st funding round was a Series B of $75M, raised on Dec 01, 2011.
How many employees does iTeos Therapeutics have?
As of Dec 31, 2022, the latest employee count at iTeos Therapeutics is 32.
What is the annual revenue of iTeos Therapeutics?
Annual revenue of iTeos Therapeutics is $35M as on Dec 31, 2024.
What does iTeos Therapeutics do?
iTeos Therapeutics was founded in 2011 and is based in Cambridge, United States. Focus is placed on immuno-oncology within the biotechnology sector, where anti-cancer agents are developed to address immuno-metabolism and immunosuppressive cells in the tumor microenvironment. Operations center on advancing a pipeline that includes an Adenosine A2A receptor antagonist currently in early-phase clinical trials, along with a TIGIT immune checkpoint blocking antibody.
Who are the top competitors of iTeos Therapeutics?
iTeos Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
What products or services does iTeos Therapeutics offer?
iTeos Therapeutics offers Belrestotug (EOS-448), EOS-984, and EOS-215.
Who are iTeos Therapeutics's investors?
iTeos Therapeutics has 20 investors. Key investors include Pfizer, Janus Henderson Investors, RTW Investments, Bpifrance, and RA Capital.